PHENIXINS share price
Phoenix Insurance PLC. · Insurance · Category A
Price
Closing prices, 19 Nov 2026 Live prices free with an account
- Previous close
- ৳45.70
- Day range
- 44.90 – 46.00
- Volume
- 1,30,722
- Turnover
- ৳59.0L
PHENIXINS price over the last year
Daily closing prices from DSE, not adjusted for bonus or rights issues.
Reported earnings and NAV
| Period | EPS | NAV / share | NOCFPS |
|---|---|---|---|
| FY26 Q3 | 0.60 | 37.01 | 1.99 |
| FY26 Q2 | 0.80 | 38.22 | 0.89 |
| FY26 Q1 | 0.65 | 35.03 | 0.40 |
| FY25 Annual | 2.02 | 33.85 | 0.56 |
| FY25 Q3 | 0.93 | 33.95 | 0.77 |
| FY25 Q2 | 0.29 | 33.13 | -0.97 |
| FY25 Q1 | 0.39 | 33.32 | 0.07 |
| FY24 Annual | 1.51 | 32.42 | 0.22 |
Per-share figures in taka, as published on DSE. Interim EPS is for the period, not annualised.
Latest DSE announcements
-
(Q3 Un-audited): EPS was Tk. 0.60 for July-September 2026 as against Tk. 0.93 for July-September 2025; EPS was Tk. 2.05 for January-September 2026 as against Tk. 1.61 for January-September 2025. NOCFPS was Tk. 1.99 for January-September 2026 as against Tk. 0.77 for January-September 2025. NAV per share was Tk. 37.01 as on September 30, 2026 and Tk. 33.95 as on September 30, 2025. (cont.)
-
(Cont. News of PHENIXINS): The Company's Earnings Per Share (EPS) increased due to net premium & others income have been increased from 3rd Quarter ended September 30, 2025. The Company's Net Asset Value (NAV) per share increased due to investment & others has been increased. The Company's Net Operating Cash Flow Per Share (NOCFPS) is higher due to collection from premium & other income has been increased. (end)
-
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 19, 2026 at 4:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended September 30, 2026.
-
The Company has informed that it has disbursed the Cash Dividend for the year ended December 31, 2025 to the respective shareholders.
-
(Q2 Un-audited): EPS was Tk. 0.80 for April-June 2026 as against Tk. 0.29 for April-June 2025; EPS was Tk. 1.45 for January-June 2026 as against Tk. 0.68 for January-June 2025. NOCFPS was Tk. 0.89 for January-June 2026 as against Tk. (0.97) for January-June 2025. NAV per share was Tk. 38.22 as on June 30, 2026 and Tk. 33.13 as on June 30, 2025. (cont.)
-
(Continuation news of PHENIXINS): Reasons for deviation: EPS increased due to net premium & others income have been increased from half yearly ended June 30, 2025. NOCFPS is higher due to collection from premium & other income has been increased. NAVPS increased due to investment & others has been increased.(end)
Other Insurance shares
| Ticker | Price | % | Turnover |
|---|---|---|---|
| REPUBLICRepublic Insurance PLC. | 40.80 | -2.63% | ৳5.5Cr |
| SIPLCSena Insurance PLC | 135.80 | -0.37% | ৳4.0Cr |
| DGICDesh General Insurance Company Limited | 43.80 | -1.35% | ৳3.8Cr |
| ISLAMIINSIslami Insurance Bangladesh Limited | 66.90 | -0.45% | ৳3.7Cr |
| BNICLBNICL | 158.00 | -2.23% | ৳3.3Cr |
| KARNAPHULIKarnaphuli Insurance PLC | 52.60 | -1.13% | ৳2.8Cr |
PHENIXINS: common questions
What is PHENIXINS's share price?
PHENIXINS closed at ৳45.20 on the Dhaka Stock Exchange (Closing prices, 19 Nov 2026), -0.50 (-1.09%) from the previous close of ৳45.70.
What is PHENIXINS's 52-week high and low?
Between 23 Nov 2025 and 19 Nov 2026, PHENIXINS traded as high as ৳57.20 and as low as ৳24.60 on DSE.
What is PHENIXINS's P/E ratio?
At ৳45.20, PHENIXINS's P/E ratio is 22.38, on its FY25 earnings per share of ৳2.02.
What dividend did PHENIXINS declare?
For 2025, Phoenix Insurance PLC. declared a 12% cash dividend. Percentages are of the ৳10 face value.
Which sector is PHENIXINS in?
Phoenix Insurance PLC. is listed in the Insurance sector of the Dhaka Stock Exchange, in category A.
Prices, trades and company figures are from the Dhaka Stock Exchange; prices are at least 15 minutes old. Trakkr is not affiliated with DSE, and nothing here is investment advice.